Comparative Pharmacology
Head-to-head clinical analysis: ACTICLATE CAP versus BISMUTH SUBCITRATE POTASSIUM METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICLATE CAP versus BISMUTH SUBCITRATE POTASSIUM METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE.
ACTICLATE CAP vs BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding.
Bismuth subcitrate potassium forms a protective coating on gastric mucosa, binds to bile acids, and has antibacterial activity against Helicobacter pylori. Metronidazole inhibits nucleic acid synthesis by disrupting bacterial DNA, while tetracycline hydrochloride inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
For Helicobacter pylori eradication: 1 tablet (bismuth subcitrate potassium 140 mg, metronidazole 125 mg, tetracycline hydrochloride 125 mg) orally 4 times daily (with meals and at bedtime) for 14 days, plus a proton pump inhibitor.
None Documented
None Documented
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
Metronidazole: 8 hours (range 6-10), prolonged in hepatic impairment; Tetracycline: 6-11 hours (normal renal function), 57-120 hours in anuria; Bismuth subcitrate: negligible systemic absorption, elimination follows transit (~24-72 hours).
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
Metronidazole: 60-80% renal (as unchanged drug and metabolites), 6-15% fecal; Tetracycline: 60% renal (glomerular filtration), 40% fecal (biliary and unabsorbed); Bismuth subcitrate: >99% fecal as insoluble bismuth sulfide.
Category C
Category D/X
Tetracycline Antibiotic
Tetracycline Antibiotic